Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 13802 | 10.37 |
09:34 ET | 1862 | 10.385 |
09:36 ET | 3061 | 10.42 |
09:38 ET | 2487 | 10.27 |
09:39 ET | 1575 | 10.33 |
09:41 ET | 2190 | 10.285 |
09:43 ET | 1060 | 10.315 |
09:45 ET | 4412 | 10.37 |
09:48 ET | 4180 | 10.39 |
09:50 ET | 2719 | 10.37 |
09:52 ET | 2967 | 10.36 |
09:54 ET | 1889 | 10.38 |
09:56 ET | 3137 | 10.39 |
09:57 ET | 1688 | 10.404 |
09:59 ET | 1901 | 10.36 |
10:01 ET | 500 | 10.36 |
10:03 ET | 1100 | 10.335 |
10:06 ET | 475 | 10.325 |
10:08 ET | 1031 | 10.34 |
10:10 ET | 1700 | 10.35 |
10:12 ET | 799 | 10.325 |
10:14 ET | 2100 | 10.275 |
10:15 ET | 500 | 10.27 |
10:17 ET | 2201 | 10.22 |
10:19 ET | 2827 | 10.185 |
10:21 ET | 2210 | 10.2 |
10:24 ET | 690 | 10.14 |
10:26 ET | 944 | 10.15 |
10:28 ET | 1336 | 10.14 |
10:30 ET | 3660 | 10.11 |
10:32 ET | 1557 | 10.085 |
10:33 ET | 2214 | 10.0477 |
10:35 ET | 4234 | 10.1 |
10:37 ET | 1049 | 10.05 |
10:39 ET | 1600 | 10.04 |
10:42 ET | 2900 | 10.12 |
10:44 ET | 500 | 10.13 |
10:46 ET | 1512 | 10.095 |
10:48 ET | 2314 | 10.13 |
10:50 ET | 2800 | 10.125 |
10:51 ET | 3207 | 10.17 |
10:53 ET | 1074 | 10.18 |
10:55 ET | 1422 | 10.215 |
10:57 ET | 1599 | 10.19 |
11:00 ET | 1450 | 10.17 |
11:02 ET | 993 | 10.17 |
11:04 ET | 1300 | 10.16 |
11:06 ET | 11980 | 10.19 |
11:08 ET | 8852 | 10.21 |
11:09 ET | 6417 | 10.15 |
11:11 ET | 4555 | 10.12 |
11:13 ET | 1469 | 10.1 |
11:15 ET | 1500 | 10.0805 |
11:18 ET | 1300 | 10.095 |
11:20 ET | 823 | 10.085 |
11:22 ET | 400 | 10.08 |
11:24 ET | 1200 | 10.06 |
11:26 ET | 950 | 10.07 |
11:27 ET | 300 | 10.06 |
11:29 ET | 950 | 10.04 |
11:31 ET | 2323 | 10.02 |
11:33 ET | 516 | 10.02 |
11:36 ET | 600 | 10.02 |
11:38 ET | 1500 | 10.01 |
11:40 ET | 400 | 9.99 |
11:42 ET | 1800 | 10.015 |
11:44 ET | 920 | 10.02 |
11:45 ET | 400 | 10.01 |
11:47 ET | 100 | 10.01 |
11:49 ET | 2659 | 10.025 |
11:51 ET | 100 | 10.02 |
11:54 ET | 420 | 10.01 |
11:56 ET | 1000 | 10.01 |
11:58 ET | 664 | 9.995 |
12:00 ET | 1100 | 9.985 |
12:02 ET | 1895 | 9.995 |
12:03 ET | 2703 | 10.018 |
12:05 ET | 300 | 10.015 |
12:07 ET | 1404 | 9.98 |
12:09 ET | 3108 | 9.97 |
12:12 ET | 1996 | 9.965 |
12:14 ET | 1122 | 9.96 |
12:16 ET | 300 | 9.96 |
12:18 ET | 4284 | 9.99 |
12:20 ET | 1100 | 9.96 |
12:21 ET | 2268 | 9.95 |
12:23 ET | 700 | 9.96 |
12:25 ET | 400 | 9.95 |
12:27 ET | 400 | 9.95 |
12:30 ET | 2500 | 9.985 |
12:32 ET | 600 | 9.98 |
12:34 ET | 500 | 9.985 |
12:36 ET | 2297 | 9.975 |
12:38 ET | 1200 | 9.97 |
12:39 ET | 2117 | 9.96 |
12:41 ET | 585 | 9.96 |
12:43 ET | 3820 | 9.96 |
12:45 ET | 1231 | 9.9025 |
12:48 ET | 1400 | 9.91 |
12:50 ET | 3525 | 9.93 |
12:52 ET | 1194 | 9.915 |
12:54 ET | 2860 | 9.915 |
12:56 ET | 600 | 9.905 |
12:57 ET | 800 | 9.915 |
12:59 ET | 5362 | 9.89 |
01:03 ET | 2900 | 9.92 |
01:06 ET | 1568 | 9.93 |
01:08 ET | 800 | 9.93 |
01:10 ET | 1518 | 9.91 |
01:12 ET | 1355 | 9.92 |
01:14 ET | 1641 | 9.92 |
01:15 ET | 600 | 9.92 |
01:17 ET | 1000 | 9.925 |
01:19 ET | 1022 | 9.9 |
01:21 ET | 1550 | 9.91 |
01:24 ET | 400 | 9.91 |
01:26 ET | 1884 | 9.9 |
01:28 ET | 2008 | 9.905 |
01:30 ET | 2314 | 9.92 |
01:32 ET | 200 | 9.9125 |
01:33 ET | 1264 | 9.92 |
01:35 ET | 7606 | 9.97 |
01:37 ET | 1464 | 9.965 |
01:39 ET | 1095 | 9.95 |
01:42 ET | 1052 | 9.94 |
01:44 ET | 900 | 9.93 |
01:46 ET | 600 | 9.92 |
01:48 ET | 813 | 9.9007 |
01:50 ET | 2499 | 9.915 |
01:51 ET | 3671 | 9.915 |
01:53 ET | 1166 | 9.935 |
01:55 ET | 2200 | 9.935 |
01:57 ET | 400 | 9.92 |
02:00 ET | 700 | 9.915 |
02:02 ET | 100 | 9.91 |
02:04 ET | 1500 | 9.925 |
02:06 ET | 3105 | 9.945 |
02:08 ET | 422 | 9.935 |
02:09 ET | 1000 | 9.92 |
02:11 ET | 500 | 9.9 |
02:13 ET | 4142 | 9.9012 |
02:15 ET | 3554 | 9.945 |
02:18 ET | 1377 | 9.925 |
02:20 ET | 2920 | 9.935 |
02:22 ET | 1300 | 9.93 |
02:24 ET | 200 | 9.9125 |
02:26 ET | 500 | 9.91 |
02:27 ET | 2208 | 9.92 |
02:29 ET | 600 | 9.9 |
02:31 ET | 1175 | 9.9 |
02:33 ET | 3469 | 9.895 |
02:36 ET | 1820 | 9.87 |
02:38 ET | 2054 | 9.8625 |
02:40 ET | 600 | 9.865 |
02:42 ET | 500 | 9.865 |
02:44 ET | 4524 | 9.875 |
02:45 ET | 1634 | 9.865 |
02:47 ET | 3083 | 9.8952 |
02:49 ET | 1348 | 9.895 |
02:51 ET | 2065 | 9.8825 |
02:54 ET | 3472 | 9.885 |
02:56 ET | 3205 | 9.91 |
02:58 ET | 600 | 9.9 |
03:00 ET | 1797 | 9.89 |
03:02 ET | 2282 | 9.9 |
03:03 ET | 2422 | 9.915 |
03:05 ET | 200 | 9.91 |
03:07 ET | 3056 | 9.925 |
03:09 ET | 700 | 9.925 |
03:12 ET | 7215 | 9.91 |
03:14 ET | 2906 | 9.895 |
03:16 ET | 600 | 9.89 |
03:18 ET | 5318 | 9.885 |
03:20 ET | 2914 | 9.885 |
03:21 ET | 3005 | 9.885 |
03:23 ET | 4370 | 9.8725 |
03:25 ET | 2600 | 9.88 |
03:27 ET | 3645 | 9.891 |
03:30 ET | 1017 | 9.885 |
03:32 ET | 3653 | 9.8951 |
03:34 ET | 3220 | 9.89 |
03:36 ET | 5023 | 9.9 |
03:38 ET | 2900 | 9.935 |
03:39 ET | 2646 | 9.925 |
03:41 ET | 2600 | 9.915 |
03:43 ET | 6830 | 9.925 |
03:45 ET | 3970 | 9.96 |
03:48 ET | 900 | 9.955 |
03:50 ET | 6070 | 9.955 |
03:52 ET | 12321 | 9.955 |
03:54 ET | 8698 | 9.955 |
03:56 ET | 14079 | 9.91 |
03:57 ET | 12343 | 9.9 |
03:59 ET | 26740 | 9.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.4B | -2.5x | --- |
Prothena Corporation PLC | 1.3B | -8.4x | --- |
Arcus Biosciences Inc | 1.5B | -3.7x | --- |
Protagonist Therapeutics Inc | 1.5B | -17.6x | --- |
Immatics NV | 1.1B | -8.3x | --- |
4D Molecular Therapeutics Inc | 1.4B | -10.4x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 17.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.